HC Wainwright & Co. maintains Buy rating on Annexon, $25 price target

HC Wainwright & Co. maintained a Buy rating and $25 price target for Annexon, implying a 633.1% upside from the Oct 16 close of $3.41. The firm highlighted Annexon's pipeline targeting unmet medical needs in autoimmune and neurodegenerative diseases.

Original reporting
Published Oct 19, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Buy rating on Annexon, $25 price target — source image
Decision brief

The 30-second read

Low
01

Why it matters

The analyst's price target suggests a large upside, but without new trial data the catalyst is primarily sentiment‑driven.

02

Market read

A new Buy rating with a high target could spark short‑term buying in ANX, but impact is limited to niche biotech investors.

03

What to watch

No recent clinical data were disclosed; the rating rests on expectations rather than new results.

Relevance 5/10Novelty 4/10Timing: today

Background

Annexon is a clinical‑stage biotech focused on complement‑mediated disorders.

Market effects

May lift sentiment for small‑cap biotech stocks.

Limited to U.S. biotech sector.

Minimal.

Counterpoint

The target may be overly optimistic given the company's early‑stage pipeline.

Key entities

  • Annexon Inc.

    Biotech developing complement pathway therapies.

  • HC Wainwright & Co.

    Equity research firm issuing the rating.

Related articles

$ANNXHigh

Wells Fargo Names Top Pick in Biotechnology Sector

Wells Fargo named Annexon, Inc. its top biotech pick, maintaining an Overweight rating and $27.00 price target. The firm cited the company's ARCHER II trial for vonaprument in generalized myasthenia gravis (GA) as a key catalyst, with a 55% success probability. Annexon has near-term catalysts, including a Q4 2026 data readout and a BLA submission. The company has $213M in cash and a $200M credit facility. Shares are down 16% YTD, underperforming the SPDR S&P Biotech ETF's 29% gain.

$ANNXMed

Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Annexon, Inc. (ANNX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in G

$ANNXMed

H.C. Wainwright raises Annexon stock price target on GBS approval prospects

H.C. Wainwright raised its price target for Annexon Biosciences (ANNX) to $25, citing catalysts like the tanruprubart BLA submission for GBS and ARCHER II readout for vonaprument. The firm values these at $11.70 and $13.60 per share, respectively. ANNX trades at $3.96, down 38% in six months, with a strong balance sheet but high cash burn. Recent Q2 loss was $0.28 per share. Other analysts also raised targets and ratings.

$ANNXMed

Annexon (ANNX) Q2 2026 Earnings Call Transcript

Annexon (ANNX) reported Q2 2026 earnings with R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M. The company has $209.2M in cash and a $200M credit facility. Key updates include ARCHER II trial progress in geographic atrophy and plans for a BLA submission for tanruprubart in Q4 2026. Management projects funding into 2028.